{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:23:31Z","timestamp":1769761411314,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.hlc.2023.11.004","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T15:36:53Z","timestamp":1704469013000},"page":"710-720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prophylaxis to Prevent Cardiotoxicity in Patients Receiving Anthracycline for Breast Cancer: A Combined Bayesian and Frequentist Network Meta-Analysis of Randomised Controlled Trials"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-9012","authenticated-orcid":false,"given":"Prajith","family":"Jeyaprakash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2670-130X","authenticated-orcid":false,"given":"Sukhman","family":"Sangha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7364-8316","authenticated-orcid":false,"given":"Gary","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-5480","authenticated-orcid":false,"given":"Christopher","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faraz","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9086-2565","authenticated-orcid":false,"given":"Kazuaki","family":"Negishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hlc.2023.11.004_bib1","first-page":"670","article-title":"The anthracyclines: will we ever find a better doxorubicin?","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.hlc.2023.11.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199700544-00003","article-title":"Anthracyclines in the treatment of cancer. An overview","volume":"54","author":"Hortob\u00e1gyi","year":"1997","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.hlc.2023.11.004_bib3","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hlc.2023.11.004_bib4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hlc.2023.11.004_bib5","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hlc.2023.11.004_bib6","series-title":"Systematic Review and Meta-analysis of Definitions and Reported Incidences of Anthracycline Cardiotoxicity","author":"Jang","year":"2019"},{"issue":"8","key":"10.1016\/j.hlc.2023.11.004_bib7","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.hlc.2023.11.004_bib8","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.hlc.2023.11.004_bib9","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u00a0\u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.004_bib10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1074248418821721","article-title":"Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial","volume":"24","author":"Nabati","year":"2019","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.hlc.2023.11.004_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15420\/ahhj.2011.9.2.95","article-title":"Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma","volume":"9","author":"Salehi","year":"2011","journal-title":"Am Heart Hosp J"},{"issue":"41","key":"10.1016\/j.hlc.2023.11.004_bib12","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.004_bib13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/annonc\/mdw671","article-title":"Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis","volume":"28","author":"Abdel-Qadir","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hlc.2023.11.004_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104577","article-title":"Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials","volume":"151","author":"Li","year":"2020","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.004_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11096-020-01146-6","article-title":"Prevention of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis","volume":"43","author":"Alizadehasl","year":"2021","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.004_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC CardioOncology"},{"issue":"3","key":"10.1016\/j.hlc.2023.11.004_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.hlc.2023.11.004_bib18","unstructured":"Collaboration C. Rev Manag (RevMan): Oxford 2015;5(3. 5)."},{"issue":"10","key":"10.1016\/j.hlc.2023.11.004_bib19","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.hlc.2023.11.004_bib20","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.004_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.hlc.2023.11.004_bib22","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2018. https:\/\/www.scirp.org\/reference\/ReferencesPapers?ReferenceID=2342186. [accessed 12.10.23]."},{"key":"10.1016\/j.hlc.2023.11.004_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.breast.2017.10.010","article-title":"Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy\u00a0+\/- trastuzumab","volume":"37","author":"Gujral","year":"2018","journal-title":"Breast (Edinb Scotl)"},{"issue":"25","key":"10.1016\/j.hlc.2023.11.004_bib24","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1002\/sim.5404","article-title":"Bayesian clinical trials in action","volume":"31","author":"Jack Lee","year":"2012","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.004_bib25","article-title":"Cardiotoxic effect of modern anthracycline dosing on left ventricular ejection fraction: A systematic review and meta-analysis of placebo arms from randomized controlled trials","volume":"10","author":"Jeyaprakash","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.hlc.2023.11.004_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","article-title":"Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in\u00a0vitro","volume":"37","author":"Spallarossa","year":"2004","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"7","key":"10.1016\/j.hlc.2023.11.004_bib27","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0735-1097(01)01683-7","article-title":"ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary","volume":"38","author":"Hunt","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.004_bib28","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.hlc.2023.11.004_bib29","first-page":"936","article-title":"[Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]","volume":"35","author":"Liu","year":"2013","journal-title":"Zhonghua Zhong Liu Za Zhi [Chin J Oncol]"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.004_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000442722","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial","volume":"134","author":"Tashakori Beheshti","year":"2016","journal-title":"Cardiology"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.004_bib31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","article-title":"Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity","volume":"69","author":"Nabati","year":"2017","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"11","key":"10.1016\/j.hlc.2023.11.004_bib32","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.hlc.2023.11.004_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MPH.0000000000001118","article-title":"Dexrazoxane significantly reduces anthracycline-induced cardiotoxicity in pediatric solid tumor patients: a systematic review","volume":"40","author":"Liesse","year":"2018","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"25A","key":"10.1016\/j.hlc.2023.11.004_bib34","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.hlc.2023.11.004_bib35","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jcmg.2018.03.019","article-title":"Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR trial","volume":"11","author":"Negishi","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Imaging"},{"issue":"26","key":"10.1016\/j.hlc.2023.11.004_bib36","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","article-title":"Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis","volume":"34","author":"Guenancia","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hlc.2023.11.004_bib37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol J"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.004_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hlc.2023.11.004_bib39","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12885-016-2761-8","article-title":"Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN)","volume":"16","author":"Pituskin","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hlc.2023.11.004_bib40","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.2147\/CMAR.S166481","article-title":"Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer","volume":"10","author":"Cochera","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"20","key":"10.1016\/j.hlc.2023.11.004_bib41","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.hlc.2023.11.004_bib42","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950623044128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950623044128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T16:41:04Z","timestamp":1729010464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950623044128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1443950623044128"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2023.11.004","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylaxis to Prevent Cardiotoxicity in Patients Receiving Anthracycline for Breast Cancer: A Combined Bayesian and Frequentist Network Meta-Analysis of Randomised Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2023.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}